secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001493152-21-027932
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics reports record Q3 revenue of $30.1M, EPS $0.38, guides FY2021 revenue $96-100M
--------------------------------------------------------------------------------

- Revenue $30.1M, up 38% YoY; gross profit $26.8M (89.0% margin).
- Net income $11.5M ($0.38 diluted EPS) vs $15.7M ($0.53) in Q3 2020.
- Cash and marketable securities $83.9M, up $11.5M from June 30, 2021.
- FY2021 guidance: revenue $96-100M, diluted EPS $1.07-$1.16, tax rate ~18%.
- Unveiled at-home/point-of-care device; JV CoSara cleared dengue/chikungunya tests in India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315221027932/0001493152-21-027932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315221027932/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-027932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer